Abstract:
Antimicrobial resistance necessitates therapeutic alternatives that expand the available options for treating bacterial infections, particularly in paediatric patients with limited pharmacological treatment options. In this context, probiotics represent a promising area of research for exploring new strategies against multidrug-resistant microorganisms.
Lactiplantibacillus plantarum LH01, isolated from human milk, is a probiotic strain that has demonstrated in vitro antimicrobial activity against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae, with inhibition rates of 89 ± 1.6% and 64 ± 2.4%, respectively. Its use as an adjunctive intervention in a paediatric patient with recurrent urinary tract infections has been associated with a reduction in the frequency of infectious episodes and bacterial burden, alongside changes in the resistance phenotype observed in follow-up cultures.
The convergence of these experimental and clinical findings has positioned LH01 as a strain of interest for the development of probiotic interventions aimed at managing recurrent infections. This approach integrates microbiology, biotechnology and clinical application, offering new possibilities for complementing conventional antimicrobial treatments. Further development of this strategy could broaden the therapeutic options available for difficult-to-treat infections and strengthen antimicrobial stewardship programmes, contributing to the search for biotechnological solutions to one of the major contemporary challenges in paediatric public health.
Biography:
Dr. Jesús Alonso Amezcua López holds a degree in Food Engineering and Biotechnology and a PhD in Biotechnological Processes from the University of Guadalajara, Mexico. He is a member of Mexico’s National System of Researchers (SNII) and works as a lecturer and researcher at the University of Guadalajara and Centro Universitario UTEG. His research focuses on paediatric nutrition, human milk preservation, probiotic development, and biotechnology applied to paediatric infections and antimicrobial resistance. He has delivered presentations at international conferences and received the 2025 Best Researcher Award in Biotechnology in Mumbai, India.
